Home

Benjamin Hickey

CIK 1753055 · President, RayzeBio Org. · last filed 2026-03-12

Benjamin Hickey is a President, RayzeBio Org. who has filed 35 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for BMY, was dated Mar 12, 2026. Across all open-market trades the lifetime net is −$1.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.23M

Companies

5

Total Filings

35

Lifetime Open-Market Net

-$1.85M

Filer Profile

Reported Address
BRISTOL-MYERS SQUIBB COMPANY
ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BMY President, RayzeBio Org. 18,344 $66.82 $1.23M -$3.7K 9 2026-03-12
MURAV Director — — — $0 5 2025-12-05
Mirati Therapeutics, Inc. (MRTX) Delisted EVP, Chief Commercial Officer 0 $58.70 $0 -$1.85M 16 2024-01-23
Surface Oncology, Inc. (SURF) Delisted Director — $1.07 — $0 2 2022-06-10
HALOZYME THERAPEUTICS, INC. (HTI) Delisted SVP, Chief Commerical Officer 13,226 — — $0 3 2019-10-01

Recent Filings

35 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-12 BMY Grant (A) — $0 EDGAR
2026-03-03 BMY Mixed +1,614 -$104.3K EDGAR
2026-02-03 BMY Mixed +6,269 -$209.7K EDGAR
2025-12-05 MURAV Disp (D) — $0 EDGAR
2025-06-13 MURAV Grant (A) — $0 EDGAR
2025-05-13 BMY Sell (S) −97 -$3.7K EDGAR
2025-03-12 BMY Grant (A) — $0 EDGAR
2025-03-04 BMY Mixed +1,656 -$97.2K EDGAR
2025-02-04 BMY Mixed +6,353 -$219.6K EDGAR
2024-06-05 MURAV Grant (A) — $0 EDGAR
Showing 1–10 of 35
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.